Endocrinology
Research Activities
Clinical Trials
Training Grant in Pediatric Endocrinology; Principal Investigator – Sharon Oberfield, MD.
(NIH/NIDDK T32DK065522-04)
Bone Mineral Density in Childhood Study; Investigator – Sharon Oberfield, MD.
(NIH/NICHD; NO1H01332-08; Site Principal)
Alterations in Androgen Metabolism, Growth Factors in Insulin Sensitivity in Premature Adrenarche, Obesity and Polycystic Ovary Syndrome – Prinicipal Investigator – Sharon Oberfield, MD (private funding)
Visceral Fat and Muscle Lipid Premature Adrenarche; Principal Investigator – Aviva Sopher, MD.
(CTSA – AAAA7793)
Diabetes and Endocrinology Research Center; Prinicpal Investigator – Dominic Accili, MD.
(NIH/NIDDK IP30 DK6068-05)
Preventing Type 2 Diabetes in School Based Settings "The Road Project" – AMDEC/STARR Foundation Corp.- Site principal investigator – Ilene Fennoy, MD, Principal Investigator - Michael Rosenbaum
A number of clinical trials and natural history studies relating to type 1 and type 2 Diabetes are conducted at the Naomi Berrie Diabetes Center; Site Prinicpal Investigator – Robin Goland, MD with Drs. Gallagher, Leibel, Softness and Fennoy participating as co-investigators. These include:
- Trial to reduce autoimmunity in the Genetically at risk; Robin Goland, MD, Site PI (TRIGR) NIH/NIDDK
UO1HD042444-07
- Treatment Options for Type 2 Diabetes in Adolescents and Youth; Natasha Leibel, MD, Co-Investigator (NIH/NIDDK U01DK061230-04)
- Environmental Determinants of Diabetes in the Young – TEDDY (NIH/NIDDK U01KD6390); Barney Softness, MD, Co-Prinicipal Investigator
- TODAY Trial (Treatment Options for Type 2 Diabetes in Adolescents and Youth (NIH/NIDDK U01DK06123040); Natasha Leibel, MD, Co-Investigator and Ilene Fennoy, MD, (Consultant)
- Multiple Trial Net Consortium Studies: (NIH/NIDDK U01DK6045), TN-05/ DE14260, 401DK61035 TN-01/DE14260, U01DK61035 TN-07/ DE14260, 401DK61035 TN-02/D14260; Co. Prinicipal Investigators – Robin Goland, MD/ Mary Pat Gallagher, MD.
Effects of Rituximab on the Program's of Type 2 Diabetes in New Onset subjects
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes
Natural History study of the Development of Type 2 Diabetes
New onset of Type 1 Diabetes Mycophenolane Mofetil-Saclizumab Clinical Trial
Open-Label, Parallel – Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin Patients with Type 1 Diabetes Mellitus, Eli-Lilly; Site Principal Investigator – Mary Pat Gallagher, MD
Additional Research Projects
In addition we have recently completed or just begun studies on the following research projects:
Dr. Fennoy completed a project that involved evaluation of the efficacy of a new method for androgen therapy.
The division was also part of a multicenter project to determine the efficacy of a newly available growth factor for treatment of growth disorders.
Dr. Shulamit Lerner was awarded an NIH K 12 investigator grant for young investigators and has completed her projects on glycosylated end products (RAGE related protocols) in mice is in the laboratory of Dr. Ann Marie Schmidt. In addition, she participated in an NIH/JDRF funded study looking at compounds to screen for prevention of Diabetic complications by blocking RAGE activation in vascular endothelium.
Abeer Hassoun, a new junior attending and graduate of our program, completed her Empire State Grant to continue post-fellowship studies on the work on infants born to women with pregnancies were complicated by gestational diabetes.
Ann Marie Francisco, our recent third year fellow worked in Dr. Anthony Ferranti's lab on immune and B-cell function. She recently received the prestigious LWPES/Novo Nordisk Research Fellowship Award to continue these studies. She also received a travel grant for the 2007 Endocrine Society Meeting factors.
Dr. Robert Levine has begun work in the lab of Gerald Karsenty M.D. studying osteocalcin and its role in obesity.
Dr. Chhavi Agarwal, who in July 2007 became an Assistant Professor of Pediatrics at Albert Einstein College of Medicine, completed work in Dr. H. Ginsberg's laboratory on lipid dysregulation and genetically altered mice lacking brown adipose tissue.
|
